What is the recommended dosage and treatment protocol for naltrexone (Naltrexone) in patients with opioid or alcohol dependence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Naltrexone Dosage and Treatment Protocol for Opioid and Alcohol Dependence

For most patients with alcohol dependence, naltrexone should be administered at a dose of 50 mg once daily for up to 12 weeks, with an initial dose of 25 mg for the first 1-3 days to assess tolerability. 1, 2, 3

Pre-Treatment Assessment

  • Opioid-Free Status:

    • Patients must be opioid-free (including tramadol) for 7-10 days before starting naltrexone 2, 3
    • For patients transitioning from buprenorphine or methadone, withdrawal symptoms may persist for up to 2 weeks 2, 3
  • Naloxone Challenge Test:

    • Recommended when occult opioid dependence is suspected 3
    • Should not be performed if patient shows clinical signs of withdrawal or has opioids in urine 3
    • Administration methods:
      • Intravenous: 0.2 mg naloxone, observe 30 seconds, then 0.6 mg if no withdrawal signs
      • Subcutaneous: 0.8 mg naloxone, observe for 20 minutes 3
  • Liver Function:

    • Baseline liver function tests required 1
    • Monitoring every 3-6 months during treatment 1

Dosing Protocol

For Alcohol Dependence:

  1. Initial dose: 25 mg daily for 1-3 days to assess tolerability 1, 3
  2. Maintenance dose: 50 mg once daily 1, 2, 3
  3. Duration: Up to 12 weeks (standard protocol from efficacy trials) 2, 3
  4. Alternative formulation: Injectable extended-release 380 mg monthly 1

For Opioid Dependence:

  1. Initial dose: 25 mg daily 2, 3
  2. Maintenance dose: 50 mg once daily if no withdrawal signs occur 2, 3
  3. Duration: Should be part of a comprehensive treatment plan 2, 3

Monitoring and Assessment

  • Evaluate treatment response at 12 weeks 1
  • Consider discontinuation if no significant reduction in drinking is observed 1
  • Regular monitoring for side effects:
    • Common side effects: nausea, vomiting, headache, dizziness, arthralgia 1
    • Hepatotoxicity concerns, especially at doses higher than 50 mg daily 1, 4

Comprehensive Treatment Approach

  • Naltrexone should be combined with:
    • Behavioral therapies (particularly Cognitive Behavioral Therapy) 1
    • Motivational interviewing techniques 5, 1
    • Community-based support groups 2, 3

Important Considerations and Cautions

  • Naltrexone blocks opioid receptors, reducing alcohol craving and consumption 4
  • Limited compliance with oral naltrexone is a known drawback; injectable depot formulations may improve adherence 6, 7
  • Naltrexone has not been extensively studied in patients with alcoholic liver disease 5, 1
  • The medication should not be used as exclusive treatment but as an adjunct to comprehensive psychosocial treatment 4

Treatment Phases

  1. Initial Phase (Weeks 1-2):

    • Begin naltrexone at 25 mg daily, then increase to 50 mg
    • Start weekly behavioral therapy sessions 1
  2. Stabilization Phase (Weeks 3-12):

    • Maintain effective naltrexone dose (50 mg daily)
    • Continue behavioral therapy 1
  3. Maintenance Phase (if continuing beyond 12 weeks):

    • Continue effective medication-assisted treatment
    • Gradually reduce frequency of behavioral therapy sessions 1

Naltrexone efficacy in clinical trials shows a modest effect size (0.15-0.2) for reducing relapse to heavy drinking, with less effectiveness for enhancing abstinence 8. However, when combined with appropriate psychosocial support and good medication compliance, it significantly improves drinking outcomes 9.

References

Guideline

Substance Use Disorder Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Naltrexone in alcohol dependence.

American family physician, 1997

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Naltrexone: Not Just for Opioids Anymore.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.